RxDoctor Payments Data

John Colton

Physician Assistant · Greenville, SCNPI 1043640956

Payments from drug & device makers

$4,115in general payments, 2019–2025

Across 240 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sanofi$421
  • Ardelyx, Inc.$357
  • Johnson & Johnson$288
  • Takeda Pharmaceuticals U.S.A., Inc.$256
  • Madrigal Pharmaceuticals$192
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,07199%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,115 in reported general payments places this provider in the 85th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$10,321
Medicare patients
113
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$312,821
XifaxanRifaximin27$85,837
LinzessLinaclotide53$68,893
Mesalamine ErMesalamine21$2,912
Ursodiol14$2,482
Omeprazole178$1,891
Colestipol Hcl20$1,856
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl89$1,361
Pantoprazole Sodium107$1,349
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$996
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl42$539
Azathioprine15$447
Sucralfate36$401
Famotidine39$363
Dicyclomine Hcl36$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$288$312,82112 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$170$85,83727 claims
AbbVieLinzess$1,063$68,89353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →